FOLEY HOAG LLP for GILEAD SCIENCES INC
No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 19, 2018 | $15,000 | Yes |
| 4th Quarter - Report (this page) | Jan 19, 2018 | — | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pending healthcare legislation and potential impact on the biopharmaceutical industry. Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing and treatment. HCV screening and linkage to care programs. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL KIM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.